Skip to content

RFN-Advanced Retrograde Femoral Nailing System

RFN-Advanced Retrograde Femoral Nailing System (RFNA) - Early Usage Case-Series Utilizing the Retrograde Femoral Nail-Advanced for Fixation and Stabilization of the Distal Femur and Femoral Shaft

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05668117
Acronym
RFNA
Enrollment
53
Registered
2022-12-29
Start date
2021-02-01
Completion date
2023-04-27
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femur Fracture

Keywords

Intramedullary Nail, Retrograde, Union

Brief summary

This study is a retrospective chart review of the safety and performance Standard of Care data on individuals that have previously been implanted with the femur nail of the RFNA System for the internal fixation of the femur. Demographics, medical history, primary diagnosis, mechanism of injury, type of injury, clinical and radiographic evaluation of bone consolidation, and device-related adverse events were collected. Descriptive statistics were applied to the data collected.

Interventions

DEVICEDepuy Synthes Advanced Retrograde femoral nail

The Advanced Retrograde Femoral Nailing System (RFNA) is designed to improve fixation and stabilization of distal femur and femoral shaft fractures by reducing toggle and loss of reduction.

Sponsors

DePuy Synthes
CollaboratorINDUSTRY
University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Subjects 18 years or older at the time of index procedure 2. Subjects who received the Depuy Synthes Advanced Retrograde Nail in accordance with the indications for use. 3. Subjects who have at least 6 months of follow-up.

Exclusion criteria

* Subject with less than 6 months of follow up, pathologic fractures, and patients \< 18 years of age will be excluded from the study.

Design outcomes

Primary

MeasureTime frameDescription
Union6 monthsRate of fracture union

Secondary

MeasureTime frameDescription
Infection6 monthsRate of infection
Implant breakage6 monthsRate of implant breakage
Implant removal6 monthsRate of symptomatic implant removal
Malunion6 monthsRate of malunion

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026